Likmez Patent Expiration

Likmez is a drug owned by Saptalis Pharmaceuticals Llc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 04, 2039. Details of Likmez's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11541035 Oral formulations of metronidazole and methods of treating an infection using same
Oct, 2039

(15 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Likmez's patents.

Given below is the list of recent legal activities going on the following patents of Likmez.

Activity Date Patent Number
Patent litigations
Email Notification 07 May, 2024 US11541035
Patent eCofC Notification 07 May, 2024 US11541035
Recordation of Patent eCertificate of Correction 07 May, 2024 US11541035
Mail Patent eCofC Notification 07 May, 2024 US11541035
Mail Certificate of Correction Memo 17 Apr, 2024 US11541035
Certificate of Correction Memo 12 Apr, 2024 US11541035
Recordation of Patent Grant Mailed 03 Jan, 2023 US11541035
Patent Issue Date Used in PTA Calculation 03 Jan, 2023 US11541035
Email Notification 15 Dec, 2022 US11541035
Issue Notification Mailed 14 Dec, 2022 US11541035

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Likmez is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Likmez's family patents as well as insights into ongoing legal events on those patents.

Likmez's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Likmez's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 04, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Likmez Generics:

Metronidazole is the generic name for the brand Likmez. 37 different companies have already filed for the generic of Likmez, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Likmez's generic

Alternative Brands for Likmez

Likmez which is used for treating symptoms of anxiety and depression., has several other brand drugs using the same active ingredient (Metronidazole). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Bausch
Metrogel-vaginal
Chemo Research Sl
Nuvessa
Galderma Labs Lp
Metrogel
Labs Juvise
Pylera
Pfizer
Flagyl Er
Teva Pharms
Vandazole


Apart from brand drugs containing the same ingredient, some generics have also been filed for Metronidazole, Likmez's active ingredient. Check the complete list of approved generic manufacturers for Likmez





About Likmez

Likmez is a drug owned by Saptalis Pharmaceuticals Llc. It is used for treating symptoms of anxiety and depression. Likmez uses Metronidazole as an active ingredient. Likmez was launched by Saptalis Pharms in 2023.

Approval Date:

Likmez was approved by FDA for market use on 22 September, 2023.

Active Ingredient:

Likmez uses Metronidazole as the active ingredient. Check out other Drugs and Companies using Metronidazole ingredient

Treatment:

Likmez is used for treating symptoms of anxiety and depression.

Dosage:

Likmez is available in suspension form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
500MG/5ML SUSPENSION Prescription ORAL